What is 68Ga-ICAM-1pep studying for cancer?

68Ga-ICAM-1pep is being studied to see if it can help predict how tumors respond to radiotherapy in cancer patients. Researchers want to understand its ability to image tumor changes during treatment. This study is led by Peking University Cancer Hospital & Institute and aims to improve cancer imaging methods.

Who may be eligible for this cancer clinical trial?

Adults aged 18 to 80 years with suspected or confirmed lung, esophagus, cervical, or other cancers may be eligible. Participants should have a good performance status and be able to undergo PET/CT imaging. This trial accepts all genders. Please review eligibility criteria for more details.

Is there any cost to participate in this cancer clinical trial?

Study-related care, including the study drug and all trial visits, is provided at no cost. However, personal travel and other expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any out-of-pocket costs.

Actively Recruiting

Early Phase 1

Age: 18Years - 80Years

All Genders

ID04596670

68Ga-ICAM-1pep PETCT Imaging of Tumor Responses to Radiotherapy in Cancer Patients

Led by Peking University Cancer Hospital & Institute · Updated on 2024-08-19

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This research aims to evaluate the use of a new imaging agent called 68Ga-ICAM-1pep in cancer patients undergoing radiotherapy. Researchers want to see if this agent can help predict the abscopal effect, a phenomenon where radiotherapy affects tumors outside the treated area. The study focuses on patients with various cancers such as lung, esophagus, and cervical cancer, and it is an early-phase clinical trial investigating this new approach. Participants will receive a single intravenous dose of 2.96 MBqkg of 68Ga-ICAM-1pep. PETCT scans will be performed about one hour after the injection. There are two groups patients who have not yet received radiotherapy and those who have completed radiotherapy. Imaging will be done before and during radiotherapy to observe tumor responses. During the study, participants will undergo PETCT scans covering from the head to the upper thigh. Researchers will measure the standardized uptake values SUVs of 68Ga-ICAM-1pep before treatment and monitor changes during radiotherapy, about 3 to 4 weeks after it begins. The study includes monitoring for compliance with imaging procedures and overall safety until the study ends in late 2025.

CONDITIONS

Brief Title

68Ga-ICAM-1pep PET/CT in Cancer Patients

Who Can Participate

Age: 18Years - 80Years

All Genders

Eligibility Criteria

You may qualify if you...

Age between 18 and 80 years
ECOG performance status score of 0 or 1
Suspected or confirmed lung cancer, esophagus cancer, cervical cancer, or other cancers recommended for PET/CT imaging by clinicians

You will not qualify if you...

Pregnant or nursing
Severe liver or kidney dysfunction
Low white blood cell count (less than 3 x 10^9/L)
Inability to comply with PET/CT imaging procedures

Research Team

Ting Zhang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here